For anyone in Cesa looking to source CJC-1295, the foundational reality is that this compound moves through online research channels. What this means for Cesa researchers is that geography is secondary to your ability to assess COA data — and those quality checks are within reach of all serious researchers. Vendors worth sourcing from make readily available batch-matched Certificates of Analysis documenting HPLC purity analysis, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the specific lot you are purchasing. Use this guide to evaluate CJC-1295 vendors rigorously — the standards covered in this guide apply whether you are in Cesa or anywhere else.
How CJC-1295 Works — Mechanisms & Research
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Cesa researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate CJC-1295 Vendors
Before evaluating any specific vendor, understand what genuine quality documentation contains — so you can recognise whether a vendor meets it. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from microbial contamination can trigger dangerous inflammatory cascades even at very low concentrations. The combination of community consensus and independent COA review is the most effective quality filter — community feedback surfaces recurring issues no single purchase reveals, and vice versa. The powdered lyophilised form of CJC-1295 is much more stable than liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations lose activity within weeks.
Order CJC-1295 — ships to Cesa
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and small-scale human observations. Proper handling of CJC-1295 requires sterile reconstitution technique — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and cold chain maintenance from receipt through use. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results reported in endotoxin units per mg or mL and confirm they fall within appropriate thresholds. Researchers running multi-compound protocols with CJC-1295 should review the available literature for documented interactions before beginning combination research.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
